rare type of small cell lung cancer that primarily affects younger people who have never ... Aug. 23, 2024 — A team of researchers has created a digital pathology platform based on artificial ...

The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t ...

American Cancer Society: “How is non-small cell lung cancer staged?” “Surgery for non-small cell lung cancer,” “Treatment choices by stage for non-small cell lung cancer,” “Radiation ...

New, Rare Type of Small Cell Lung Cancer Identified Sep. 11 ... Aug. 23, 2024 — A team of researchers has created a digital pathology platform based on artificial intelligence.

Beyond Standard of Care NYU lung cancer specialists discuss advances in adjuvant therapy for non–small cell lung cancer, including targeted therapy. Teamwork: A Multidisciplinary Approach to ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...

Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The non-small cell lung cancer (NSCLC) drug osimertinib (Tagrisso) was associated ...

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...

Opens in a new tab or window EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, even after undergoing systemic therapy ...

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and ...

More than 80% of patients with lung cancer receive care in their communities, but this can leave them vulnerable to gaps in care quality and delivery. Amivantamab's role in non–small cell lung ...